Recently, Luoqi Biological announced to complete the A-round financing of billion yuan. This round of financing is led by Tianhui Capital, co-invested by Taiyu Investment and Fuhui Venture Capital, and Haoyue Capital serves as the exclusive financial adviser of this round of financing.

This round of financing is mainly used to promote the IND application and clinical research of inhaled nanoantibody asthma treatment drugs, as well as the development of other follow-up pipeline projects. In addition, Loki is also about to build a 500L GMP Pichia pastoris production plant that meets the requirements of clinical phase II sample preparation. In the next 1-2 years, three products will also enter the clinical research stage.

Dr. Wan Yakun, CEO of Loqi Biologics, said that Loqi Biologics is a research and development company of nano-antibody bio-pharmaceuticals focusing on the whole industrial chain, committed to the industrialization of innovative bio-pharmaceutical achievements and the research and development of targeted new drugs, established a complete development system of nano-antibody new drugs, effectively combined the early screening of nano-antibodies with the late process development of candidate drugs, and formed a systematic and complete research and development system, It is at the leading level in the industry at home and even internationally. The success of this round of financing provides a strong guarantee for the rapid promotion of the clinical application and development of the company's new drug projects. Thank you very much for your high recognition of our team and project! We will continue to work in the fields of respiratory and autoimmune diseases and accelerate the clinical application and development of corresponding products.

About Tianhui Capital

Tianhui Capital (i.e. Tianhui Hongyou&Tianhui Sumin Investment) is a value investor and navigator who has deeply cultivated the medical and health industry. The core team of the company has been engaged in the investment management of the medical and health industry for nearly 20 years, and has adopted the "four modernizations" investment strategy of "specialization, early stage, platform and internationalization", focusing on key areas such as precision medicine, high-end medical devices, innovative drugs and new treatment technologies; The company has systematically built a unique post-investment management system such as "1+1+N" and "100-day navigation assistance". Through professional post-investment value-added services, it has accelerated the innovation, transformation and leapfrog development of domestic medical and health industry and joint-stock enterprises. The typical investment cases of the company and the team mainly include: Xiansheng Pharmaceutical (02096. HK), Dongrui Pharmaceutical (02348. HK), Erye Pharmaceutical, Hongqi Pharmaceutical, Aohong Pharmaceutical, Jinhe Industrial (002597. SZ), Longmang Baili (002601. SZ), Nanotech, Shihe Gene, McKinnocaine, Nuoyuan Medical, Terui Pharmaceutical, Dean Diagnostics (300244. SZ), Hanhai New Enzyme, Tengchen Biological, Livada, Bosheng Biological, Xuankai Biological, Xiansheng Diagnostics Anhui Wanbang Pharmaceutical, Maiji Biology, Yannuo Pharmaceutical, Youmai Biology, etc.

About Taiyu Investment

Taiyu Investment is an independent professional venture capital company under Taige Pharmaceutical, a listed company, established in 2014. Taiyu Investment focuses on equity investment in the early and growing medical and health sectors. The management team has a profound background in the medical and health industry, extensive industry resources and rich experience in venture capital. So far, it has completed more than 1 billion yuan of investment and financing and early equity investment in more than 40 projects, most of which are investment institutions in the first or pre-A round, and the investment portfolio covers medical devices, biological medicine, health food, and CRO enterprises. By empowering the invested enterprises, Taiyu Investment creates value for the development of China's and even the global medical and health industry, and makes contributions to public health.

About Fuhui Venture Capital

Since its establishment in 2008, Fuhui Venture Capital has managed a total of 10 funds with assets under management of nearly 3 billion yuan, invested in more than 50 enterprises, focused on the transformation of scientific and technological achievements and early investment in scientific and technological enterprises, and incubated a number of scientific and technological achievements of the Chinese Academy of Sciences and excellent early scientific and technological enterprises; It mainly invests in medicine and health, TMT/advanced manufacturing and other fields. The drug fund recently launched by Fuhui Venture Capital is mainly invested in biomedical preclinical research, IND, and clinical experiment phase I-II projects, focusing on innovative traditional Chinese medicine, chemicals, and biological medicine projects such as antibody drugs, cell therapy, and other high-tech projects in the field of general health, such as malignant tumors, cardiovascular and cerebrovascular diseases, neuropsychiatric diseases, metabolic diseases, autoimmune diseases, and infectious diseases.

About novamab

Luoqi Biology was established in Shanghai International Medical Park in 2017, and was recognized as a national high-tech enterprise in 2020. It has a research and development base of more than 2500 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nano-antibody: nano-antibody rapid screening platform, Pichia pastoris CMC process development platform, inhaled macromolecular drug research and development platform, nano-antibody long-acting platform and nano-antibody dual-antibody platform. Each platform has very unique industry advantages, which can quickly screen out nano-antibody drugs with drug activity and rapidly industrialization. Dr. Wan Yakun, the founder of the company, is a pioneer in the field of nanoantibody in China. He served as the director of the first nanoantibody research center in China and applied for more than 40 invention patents related to nanoantibody.

洛启生物招贤纳士火热进行中~

应聘热线：朱女士 021-20985259

应聘邮箱：hr@novamab.com（简历标题：姓名+学历+专业+应聘岗位）